Company Filing History:
Years Active: 2022-2025
Title: Lina Kong: Innovator in Nucleic Acid Research
Introduction
Lina Kong is a prominent inventor based in Suzhou, China. She has made significant contributions to the field of nucleic acid research, particularly in the development of innovative pharmaceutical compositions. With a total of 2 patents, her work focuses on the inhibition of specific gene expressions, which has important implications for medical science.
Latest Patents
Lina Kong's latest patents include groundbreaking inventions related to nucleic acids. One of her patents describes a siRNA designed to inhibit the expression of the angiopoietin-like protein 3 (ANGPTL3) gene. This siRNA is characterized by a pharmaceutical composition and a conjugate that includes the siRNA, where each nucleotide can be either modified or unmodified. The siRNA consists of a sense strand and an antisense strand, with specific nucleotide sequences that allow for precise gene targeting. Another patent similarly focuses on the same siRNA and its applications in inhibiting ANGPTL3 gene expression, showcasing her dedication to advancing therapeutic methods.
Career Highlights
Lina Kong is currently employed at Suzhou Ribo Life Science Company, Ltd., where she continues to push the boundaries of nucleic acid research. Her work has garnered attention in the scientific community, and she is recognized for her innovative approaches to gene therapy.
Collaborations
Lina collaborates with esteemed colleagues, including Hongyan Zhang and Shan Gao, who contribute to her research endeavors. Their combined expertise enhances the potential impact of their work in the field of biotechnology.
Conclusion
Lina Kong is a trailblazer in nucleic acid research, with a focus on innovative solutions for gene expression inhibition. Her contributions are paving the way for advancements in medical treatments and therapies.